Polarean Imaging Share Discussion Threads

[moontheloon] 23/8/2024 12:09

And bones wrong again. Not an investor... what does he have in life? Not much at a guess

[moontheloon] 23/8/2024 12:07

Getting accurate calling these ticks :)

[moontheloon] 23/8/2024 11:50

Tick up incoming end the week blue would be a good week! Setting us up to just over a week to results and presentation and q&a and increased clarity

[bones698] 23/8/2024 06:12

Heading back down as traders get their 10% . Range bound until news imo

[moontheloon] 21/8/2024 10:37

1.75p offer incoming. Let's keep the buying up to results

[moontheloon] 21/8/2024 10:23

Previous factual logging of revenue via rns'd factual commercialisation points to just good solid revenue and progress

[aberloon2] 21/8/2024 09:54

Since, in POLX's own words that they are a revenue-generating medical imaging technology company, i hope to see some rockets this time instead of the previous damp squibs...

[moontheloon] 21/8/2024 08:42

1.7 offer incoming

[moontheloon] 19/8/2024 12:13

Last chance to buy at 1.6p bonehead

[moontheloon] 19/8/2024 07:24

3 additional clinical deals signed in July. More to come in August.And factually ahead of forecasts and revenue guidance for 2024. You have your 4 letter words mixed up. FACT not RAMP.none needed next deal will ramp naturally. Thanks for wasted input however comme toujours

[bones698] 19/8/2024 07:10

Meanwhile in the real world the share price continues to fall despite moon the loons desperate attempts to ramp .

Shares are still being churnednfrom.thebplaximf with sellers around offloading . Looks like it will be a while yet before this settles

Also deals are to slow and losses far too high meaning more funding will be required in the future . Until revenues approach 10m this will burn through cash far to fast and they haven't reduced costs enough

[moontheloon] 16/8/2024 08:50

Keep accumulating at this price. 6 month Results mid next month. We all know we've already beaten expectations for 2024. So only way is up

[moontheloon] 07/8/2024 15:55

Keep the buys coming tomorrow get to the 1.9 threshold again with an assault on 2p by end of week.Still expecting high potential of newslow every 7am. Think cvj personally getting us lined up for TO which he specialises in. Which will land out of the blue in the next 6 months.There's enough clinical commercial proof now to make this a very tasty acquisition for peanuts

[moontheloon] 07/8/2024 14:57

Blue day incoming

[moontheloon] 07/8/2024 07:53

Mms fudging buys as sells.

[john henry] 01/8/2024 14:25

Imho there are still millions of Open Offer shares to churn through.

[moontheloon] 01/8/2024 07:43

Need the 500k and millions to get us above 2p at some point. A share rec would do it. Which is more likely now post raise and the speed of commercialism

[moontheloon] 01/8/2024 07:42

Absolutely and Absolutely no reason to sell at present.

[john henry] 01/8/2024 07:33

some solid buying so far today.

[moontheloon] 01/8/2024 06:14

So approx 3 months for results of this application. Should realistically expect another 2 to 3 sites to have been gained as conversion to clinical or de novo by then

[moontheloon] 01/8/2024 06:02

Nice and regular on the rns

[moontheloon] 01/8/2024 06:02

Polarean Imaging PLC FDA submission to expand minimum age for XENOVIEW™Source: RNS Regulatory News?RNS Number : 7522YPolarean Imaging PLC01 August 2024 ?Polarean Imaging Plc("Polarean" or the "Company") FDA submission to expand minimum age for XENOVIEW™ Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that it has submitted a New Drug Application ("NDA") supplement to the US Food and Drug Administration ("FDA"), to allow the administration of XENOVIEW™ to paediatric patients aged six years and older. This supplement includes updates to the HPX Polarisation Measurement Station and new XENOVIEW™ Dose Delivery Bag sizes. Currently XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. Christopher von Jako, Ph.D, Chief Executive Officer of Polarean, said: "I am pleased to have submitted our NDA supplement to the FDA to expand the minimum age of XENOVIEW™ to paediatric patients six years and older. If granted, this will allow our technology to help even more children with chronic lung conditions and their clinicians, allowing for better management of their disease. I look forward to further updating the market in due course." Enquiries: Polarean Imaging plc www.polarean.com / www.polarean-ir.com Christopher von Jako, Ph.D, Chief Executive Officer Charles Osborne, Chief Financial OfficerVia Walbrook PR   Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)[phone]Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)Nick Harland (Corporate Broking) Walbrook PR Tel: [phone] or [e-mail] Dunphy / Phillip MarriageMob: [phone] / [phone] ?About Polarean Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com. XENOVIEW IMPORTANT SAFETY INFORMATION  IndicationXENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. Limitations of UseXENOVIEW has not been evaluated for use with lung perfusion imaging. CONTRAINDICATIONSNone. Warnings and PrecautionsRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold. Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated. Adverse Reactions Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age. Please see full prescribing information at www.XENOVIEW.net This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END  MSCPBMATMTJMMLI